Association of Early Postoperative Biochemical Markers with a Composite Adverse Perioperative Outcome After Bariatric Surgery
Diagnostics · 25.07.2026 · 16 (15) · 2332
DOI: 10.3390/diagnostics16152332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diagnostics, online erschienen am 25.07.2026. Verfasst von Bahar Uslu Bayhan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Reanimation, Gaziantep City Hospital, Gaziantep 27010, Türkiye. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Bariatric surgery is the most effective treatment for sustained weight loss; however, early postoperative complications remain a significant concern. Routine biochemical markers obtained in the immediate postoperative period may enable early risk stratification, yet their prognostic value remains incompletely defined. This study aimed to evaluate the association between early postoperative biochemical alterations and composite adverse outcomes after bariatric surgery.
Methods
In this retrospective observational study, 260 adult patients undergoing elective bariatric surgery were included. Preoperative and postoperative day 1 (POD1) laboratory parameters were retrieved from electronic medical records. The primary endpoint was a composite adverse outcome comprising postoperative intensive care unit admission, infection, anastomotic leak, or 30-day readmission. Univariable and multivariable logistic regression analyses were performed to evaluate independent associations, and receiver operating characteristic (ROC) curve analysis was used to assess discriminative performance.
Results
Composite adverse outcomes occurred in 51 patients (19.6%). In multivariable analysis, longer operative duration (OR 1.17 per 10 min, 95% CI 1.04–1.31; p = 0.009), POD1 AST (OR 1.15 per 10 U/L, 95% CI 1.07–1.24; p < 0.001), and POD1 lactate-to-albumin ratio (LAR ×100) (OR 1.20, 95% CI 1.04–1.38; p = 0.014) were independently associated with adverse outcomes. POD1 AST demonstrated the highest discriminative ability (AUC 0.733), followed by glucose (AUC 0.688) and ALT (AUC 0.680), whereas LAR showed limited stand-alone performance (AUC 0.594).
Conclusions
Longer operative duration and higher POD1 AST and LAR levels were independently associated with the composite adverse perioperative outcome. AST showed the highest, although moderate, individual discrimination, whereas LAR demonstrated limited stand-alone performance. Because immediate postoperative ICU transfer preceded POD1 biomarker sampling and dominated the composite outcome, these findings should be interpreted as associations rather than prospective prediction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology and Reanimation, Gaziantep City Hospital, Gaziantep 27010, Türkiye.
- Department of General Surgery, Gaziantep City Hospital, Gaziantep 27010, Türkiye.
ORCID-Profile: Bahar Uslu Bayhan, Tugçe Gazioglu Kisi, Muhammed Gokhan Abay, Bulent Sultanoglu
Zitieren
APA
Bayhan, B. U., Gazioglu Kisi, T., Akinci, G., Abay, M. G., & Sultanoglu, B. (2026). Association of Early Postoperative Biochemical Markers with a Composite Adverse Perioperative Outcome After Bariatric Surgery. Diagnostics, 16(15), 2332. https://doi.org/10.3390/diagnostics16152332
Vancouver
Bayhan BU, Gazioglu Kisi T, Akinci G, Abay MG, Sultanoglu B. Association of Early Postoperative Biochemical Markers with a Composite Adverse Perioperative Outcome After Bariatric Surgery. Diagnostics. 2026;16(15):2332. doi:10.3390/diagnostics16152332
BibTeX
@article{Bayhan2026,
author = {Bayhan, Bahar Uslu and Gazioglu Kisi, Tugçe and Akinci, Gulay and Abay, Muhammed Gokhan and Sultanoglu, Bulent},
title = {Association of Early Postoperative Biochemical Markers with a Composite Adverse Perioperative Outcome After Bariatric Surgery},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {15},
pages = {2332},
doi = {10.3390/diagnostics16152332}
}
EUVIMED